Literature DB >> 12019177

Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model.

Yanlin Yu1, Glenn Merlino.   

Abstract

Normal cells are dependent on exogenous, receptor-mediated growth stimulation for cell cycle entry and progression, providing a critical homeostatic mechanism regulating cellular proliferation. In contrast, tumor cells acquire some degree of growth signal autonomy, often through their ability to produce growth factors as well as their receptors (autocrine signaling). Recently, data have begun to emerge implicating heterotypic signaling between diverse cell types within a tumor in the genesis and progression of cancer; however, current experimental approaches in vivo have not adequately addressed this critical relationship. Here we used transgenic mice overexpressing hepatocyte growth factor/scatter factor (HGF/SF), or its growth antagonist NK2, as genetically modified hosts for transplantation of tumor cells expressing their receptor, c-Met, to directly assess the contribution of heterotypic signaling to metastatic colonization. We demonstrate that metastatic potential under nonautocrine signaling conditions (i.e., where tumor cells expressing c-Met are transplanted into transgenic hosts producing HGF/SF) rivaled that observed under conditions of autocrine signaling (i.e., where tumor cells expressing both HGF/SF and c-Met are transplanted into wild-type hosts). HGF/SF and NK2 were not functionally equivalent in vivo. Attenuation of NK2-associated growth inhibition by the presence of an HGF/SF-Met autocrine loop uncovered a shift in metastatic site preference from lung to liver only in NK2-transgenic hosts, a qualitative behavioral alteration likely detectable only through the genetic approach used here. Our data demonstrate that growth factors not intrinsic to malignant cells can have profound effects on metastatic efficiency in vivo and provide experimental support of a role for heterotypic signaling in tumor progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019177

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

Review 1.  Targeting the HGF/Met signaling pathway in cancer therapy.

Authors:  Fabiola Cecchi; Danie C Rabe; Donald P Bottaro
Journal:  Expert Opin Ther Targets       Date:  2012-04-25       Impact factor: 6.902

2.  Overexpression of NK2 inhibits liver regeneration after partial hepatectomy in mice.

Authors:  Toshiyuki Otsuka; Norio Horiguchi; Daisuke Kanda; Takashi Kosone; Yuichi Yamazaki; Kazuhisa Yuasa; Naondo Sohara; Satoru Kakizaki; Ken Sato; Hitoshi Takagi; Glenn Merlino; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

3.  Roles for aberrant CXCR3 signaling in basal cell carcinoma: a case for dual activity.

Authors:  Yanlin Yu; Glenn Merlino
Journal:  Am J Pathol       Date:  2010-02-25       Impact factor: 4.307

4.  The MET axis as a therapeutic target.

Authors:  Martin Sattler; Ravi Salgia
Journal:  Update Cancer Ther       Date:  2009-04-01

Review 5.  MET overexpression and gene amplification in NSCLC: a clinical perspective.

Authors:  Lorenza Landi; Gabriele Minuti; Armida D'Incecco; Jessica Salvini; Federico Cappuzzo
Journal:  Lung Cancer (Auckl)       Date:  2013-06-18

6.  Ezrin mediates both HGF/Met autocrine and non-autocrine signaling-induced metastasis in melanoma.

Authors:  Liping Huang; Yifei Qin; Qiang Zuo; Kavita Bhatnagar; Jingbo Xiong; Glenn Merlino; Yanlin Yu
Journal:  Int J Cancer       Date:  2017-12-15       Impact factor: 7.396

7.  PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.

Authors:  Yanlin Yu; Meng Dai; Andrew Lu; Ellen Yu; Glenn Merlino
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

8.  Molecular magnetic resonance imaging approaches used to aid in the understanding of the tissue regeneration marker Met in vivo: implications for tissue engineering.

Authors:  Rheal A Towner; Nataliya Smith; Yasuko Asano; Sabrina Doblas; Debra Saunders; Robert Silasi-Mansat; Florea Lupu
Journal:  Tissue Eng Part A       Date:  2010-02       Impact factor: 3.845

9.  Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene.

Authors:  Yanlin Yu; Pingyao Zeng; Jingbo Xiong; Ziyang Liu; Shelley L Berger; Glenn Merlino
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

Review 10.  c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.

Authors:  Martin Sattler; Ravi Salgia
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.